-Outlook Arvind Kejriwal’s public rift with Anna must not distract us from the necessity of his political foray  Anna Hazare may not be part of the proposed political party that is yet to emerge from the womb of what was an unprecedented movement against corruption. The questions he has raised, however, must be answered. Not just because they are his questions; he being the symbol of probity in public life. They need...

-The Economic Times NEW DELHI: Birla ho ya Tata, Ambani ho ya Bata Sabne apne chakkar mein des ko hai kaata Are humre hi khoon se inka Engine chale dhakadhak (Be it Birla or Tata, Ambani or Bata Everyone has exploited the nation for their own benefit Their engine runs on our blood) The names of some of India's top corporate houses may seem to rhyme well in this Bollywood ballad, but its drift, insinuating that business groups like...

-The Hindu Icann, the global authority dealing with domain names, is hastening the threat of monopolisation on the internet through its new scheme to sell generic words L’Oréal has applied for the top level domain (TLD) .beauty to the Internet Corporation for Assigned Names and Numbers (Icann), the global authority dealing with domain names on the Internet. TLDs are what we see on the right side of the dot in domain names...

-The Telegraph The CPM today disclosed that levy collected from party members plus small, voluntary contributions had swelled its coffers but denied it was a big beneficiary of corporate donations. “The CPI(M) does not accept donations from corporates. However, there have been contributions from some companies in Andhra Pradesh. These donations, when it came to the notice of the politburo last year, was discussed and it was decided not to accept donations...

-The Indian Express India may not be a testing hub for Big Pharma. But informed consent must be non-negotiable Figures released by the World Health Organisation, which show that 10 Indian subjects of clinical field trials die every week, have rekindled concerns that this country has become a testing hub for Big Pharma. Ironically, the same figures deflate this persistent fear, revealing that only 1.5 per cent of global trials have been...